Form 4: Immunovant COO Acquires Stock Options and RSUs

Immunovant, Inc. reports that Chief Operating Officer Melanie Gloria acquired stock options and restricted stock units on April 7, 2026.

Summary

• Melanie Gloria, Chief Operating Officer of Immunovant, Inc., acquired 83,671 restricted stock units (RSUs) and 121,063 stock options on April 7, 2026.
• The RSUs were granted under the Issuer's 2019 Equity Incentive Plan and will vest starting April 1, 2027, with 25% vesting then and the remainder over twelve quarterly installments.
• The stock options, also granted under the 2019 Equity Incentive Plan, have an exercise price of $24.61 and will vest starting April 1, 2027, with 25% vesting then and the remainder over thirty-six monthly installments.
• Following these transactions, Gloria beneficially owns 253,944 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard executive compensation practices and insider acquisition of equity, indicating continued commitment rather than significant new financial information.

Positives

• The Chief Operating Officer has acquired a significant number of equity awards, indicating confidence in the company's future prospects.
• The equity awards are structured with vesting schedules, aligning the COO's incentives with long-term company performance and employee retention.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• Vesting of RSUs and stock options is contingent on the Reporting Person's continuous service to the Issuer, implying a risk of forfeiture if service is not maintained.
• The stock options have an exercise price of $24.61, meaning they will only be profitable if the stock price exceeds this level.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a forward-looking perspective on the company's growth and the executive's continued involvement.

Industry Context

StockSavvy.ai notes that the acquisition of equity awards by a Chief Operating Officer is a common practice in the biotechnology and pharmaceutical sectors, often used to attract and retain key talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of equity by a key executive can be seen as a positive signal of commitment and alignment with shareholder interests.
• Employees: The equity incentive plan structure suggests a broader framework for employee compensation and retention.
• Management: The COO's acquisition of equity reinforces their role and potential future financial stake in the company's success.

Next Steps

• Vesting of RSUs and stock options according to the specified schedules.
• Continued service by the Reporting Person to Immunovant, Inc.

Key Dates

Keywords

Immunovant, IMVT, Form 4, Insider Trading, Stock Options, RSUs, Equity Incentive Plan, Melanie Gloria, Chief Operating Officer, Beneficial Ownership